Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases

Background Currently, only few techniques are available for quantifying systemic metastases in preclinical model. Thus techniques that can sensitively detect metastatic colonization and assess treatment response in real-time are urgently needed. To this end, we engineered tumor cells to express a naturally secreted Gaussia luciferase (Gluc), and investigated its use as a circulating biomarker for monitoring viable metastatic or primary tumor growth and their treatment responses. Methodology/Principal Findings We first developed orthotopic primary and metastatic breast tumors with derivative of MDA-MB-231 cells expressing Gluc. We then correlated tumor burden with Gluc activity in the blood and urine along with bioluminescent imaging (BLI). Second, we utilized blood Gluc assay to monitor treatment response to lapatinib in an experimental model of systemic metastasis. We observed good correlation between the primary tumor volume and Gluc concentration in blood (R2 = 0.84) and urine (R2 = 0.55) in the breast tumor model. The correlation deviated as a primary tumor grew due to a reduction in viable tumor fraction. This was also supported by our mathematical models for tumor growth to compare the total and viable tumor burden in our model. In the experimental metastasis model, we found numerous brain metastases as well as systemic metastases including bone and lungs. Importantly, blood Gluc assay revealed early growth of metastatic tumors before BLI could visualize their presence. Using secreted Gluc, we localized systemic metastases by BLI and quantitatively monitored the total viable metastatic tumor burden by blood Gluc assay during the course of treatment with lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2. Conclusion/Significance We demonstrated secreted Gluc assay accurately reflects the amount of viable cancer cells in primary and metastatic tumors. Blood Gluc activity not only tracks metastatic tumor progression but also serves as a longitudinal biomarker for tumor response to treatments.

[1]  M. Murphy,et al.  Activation of cancer-specific gene expression by the survivin promoter. , 2002, Journal of the National Cancer Institute.

[2]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[3]  Ralph Weissleder,et al.  A secreted luciferase for ex vivo monitoring of in vivo processes , 2008, Nature Methods.

[4]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  B. Tannous,et al.  Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo , 2009, Nature Protocols.

[6]  X. Breakefield,et al.  Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells , 2007, Proceedings of the National Academy of Sciences.

[7]  Christopher H Contag,et al.  In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. , 2007, Annual review of pathology.

[8]  R. Weissleder,et al.  Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  M. Selvakumaran,et al.  Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. , 2000, Gynecologic oncology.

[10]  S. Gambhir,et al.  Optical imaging of Renilla luciferase reporter gene expression in living mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Michel Sadelain,et al.  Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase , 2009, Nature Medicine.

[12]  K. Lackey,et al.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[13]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[14]  S. Steinberg,et al.  Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.

[15]  M. Kitamura,et al.  Secreted protein-based reporter systems for monitoring inflammatory events: critical interference by endoplasmic reticulum stress. , 2006, Journal of immunological methods.

[16]  Xin Lu,et al.  Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis , 2009, Nature Medicine.

[17]  Jian Yao,et al.  Continuous, noninvasive monitoring of local microscopic inflammation using a genetically engineered cell-based biosensor , 2005, Laboratory Investigation.

[18]  D. Lee,et al.  In Vivo Imaging of Functional Targeting of miR-221 in Papillary Thyroid Carcinoma , 2008, Journal of Nuclear Medicine.

[19]  B. Rice,et al.  In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.

[20]  X. Breakefield,et al.  A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress , 2007, PloS one.

[21]  C. Contag,et al.  Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. , 2005, Journal of biomedical optics.